8-K: CareDx Anticipates Strong Revenue Growth in Preliminary Q4 and Full Year 2024 Results

CareDx reports preliminary Q4 2024 revenue expected to increase by 30% year-over-year, with full year 2024 revenue projected between $332 million and $333 million.

Summary

• CareDx anticipates revenue between $85 million and $86 million for the fourth quarter of 2024, representing a 30% year-over-year increase.
• Testing services revenue is expected to be between $62.5 million and $63.5 million, a 35% increase year-over-year, with testing services volume reaching approximately 45,500, up 14%.
• Digital Solutions and Products are each expected to generate $11.4 million in revenue.
• The company projects a GAAP loss of $32 million to $34 million and an adjusted EBITDA gain of $8 million to $9 million for Q4 2024.
• For the full year 2024, CareDx expects revenue between $332 million and $333 million.
• The full year GAAP loss is projected to be between $58 million and $60 million, with an adjusted EBITDA gain of $25 million to $26 million.
• CareDx expects to have approximately $261 million in cash, cash equivalents, and marketable securities as of December 31, 2024, an increase of $26 million year-over-year.
• The company provides 2025 revenue guidance of $370 million.
• CareDx aims to achieve $500 million in revenue and a 20% adjusted EBITDA margin by 2027.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, increasing testing volumes, and a healthy cash balance. The company is on track to achieve its long-term financial targets, contributing to a favorable sentiment.

Positives

• CareDx anticipates strong revenue growth in Q4 and full year 2024.
• Testing services revenue and volume are increasing significantly.
• The company has a healthy cash balance and expects it to increase year-over-year.
• CareDx is providing positive revenue guidance for 2025.
• The company is on track to achieve its long-term financial targets.

Negatives

• CareDx expects to report a GAAP loss for both Q4 and full year 2024, although adjusted EBITDA is positive.
• The preliminary financial results are subject to change pending completion of the annual audit.

Risks

• The preliminary financial information is based on current expectations and may be adjusted upon completion of customary annual audit procedures.
• General economic and market factors, as well as global economic and marketplace uncertainties, could impact actual results.
• Risks and uncertainties detailed in CareDx's filings with the SEC could cause actual results to differ materially from forward-looking statements.

Future Outlook

CareDx anticipates revenue of $370 million during 2025 and aims to achieve $500 million in revenue and 20% adjusted EBITDA in 2027.

Management Comments

• John W. Hanna, CareDx President and CEO, stated that the company achieved its sixth consecutive quarter of testing services volume growth in Q4.
• John W. Hanna, CareDx President and CEO, stated that the company is well-positioned for another successful year of growth in 2025 and on pace to achieve its targets of $500 million in revenue and 20% adjusted EBITDA in 2027.

Industry Context

CareDx is a leading precision medicine solutions company focused on transplant patients, and the announcement reflects the growing demand for transplant monitoring and diagnostic services. The company's expansion into cell therapy monitoring positions it to capitalize on emerging opportunities in that field.

Comparison to Industry Standards

• CareDx's growth in testing services volume and revenue aligns with the broader trend of increasing adoption of genomics-based diagnostics in transplant care.
• Companies like Natera and Eurofins Scientific also operate in the transplant diagnostics space, and CareDx's performance can be benchmarked against their growth rates and market share.
• The target of 20% adjusted EBITDA by 2027 is a common profitability goal for companies in the diagnostics industry, and achieving this target would position CareDx favorably compared to its peers.

Stakeholder Impact

• Shareholders can expect continued growth and potential for increased profitability.
• Transplant patients will benefit from the company's focus on developing and commercializing innovative diagnostic solutions.
• Employees can anticipate opportunities for career advancement and professional development.
• The company's growth will create value for suppliers and partners in the transplant ecosystem.

Next Steps

• CareDx will report on the fourth quarter and full year 2024 financial results and anticipates providing 2025 financial guidance on its February 2025 earnings call.

Key Dates